Reset filter
Palabras clave
C06.405.249.767 ×
Mostrar más Palabras clave
Tabla de contenido
  1. 1. Ensayo clínico
  2. 2. Documentación de rutina
  3. 3. Estudio de registro / cohorte
  4. 4. Seguro de calidad
  5. 5. Estándar de datos
  6. 6. Resultado reportado por el paciente
  7. 7. Especialidad médica
    1. 7.1. Anestesiología
    1. 7.2. Dermatología
    1. 7.3. ENT
    1. 7.4. Geriatría
    1. 7.5. Ginecología / Obstetricia
    1. 7.6. Medicina Interna
      1. Hematología
      1. Enfermedades infecciosas
      1. Cardiología / Angiología
      1. Neumología
      1. Gastroenterología
      1. Nefrología
      1. Endocrinología / Enfermedades metabólicas
      1. Reumatología
    1. 7.7. Neurología
    1. 7.8. Oftalmología
    1. 7.9. Cuidados paliativos
    1. 7.10. Patología / Forense
    1. 7.11. Pediatría
    1. 7.12. Psiquiatría / Psicosomática
    1. 7.13. Radiología
    1. 7.14. Cirugía
      1. Cirugía General / Visceral
      1. Neurocirugía
      1. Cirugía plástica
      1. Cirugía Torácica
      1. Traumatología / Ortopedia
      1. Cirugía vascular
    1. 7.15. Urología
    1. 7.16. Odontología / OMS
Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

54 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

dbGaP phs001003 Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets - pht010322.v2.p1

- 6/11/23 - 6 formularios, 1 itemgroup, 2 items, 1 idioma
Itemgroup: pht010322
Principal Investigator: Steven A. Rosenberg, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Colonic Neoplasms,Ovarian Neoplasms,Stomach Neoplasms,Cholangiocarcinoma,Pancreatic Neoplasms,Rectal Neoplasms,Esophageal Neoplasms,Colorectal Neoplasms,Endometrial Neoplasms,Paraneoplastic Syndromes, Ocular https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001003 Recent advances and insights into the molecular pathogenesis of cancer have led to the development of novel molecular and biologic targeted therapies for the treatment of advanced cancer patients. A critical challenge in extending these studies involves the identification and validation of new therapeutic targets for future cancer therapies. In this study, we performed whole exome and RNA-Seq analysis metastases to determine the nature and frequency of somatic mutations.

pht010323.v2.p1

1 itemgroup 2 items

pht010324.v2.p1

1 itemgroup 4 items

pht010325.v1.p1

1 itemgroup 2 items

pht010326.v2.p1

1 itemgroup 5 items

Eligibility

1 itemgroup 9 items

NCT00486954_Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer - Safety Assessment of Interstitial Pneumonitis, Continutation, Status, Concominant Medications

- 29/5/18 - 1 formulario, 4 itemgroups, 11 items, 1 idioma
Itemgroups: Safety Assessment of Interstitial Pneumonitis, Continutation, Status, Concominant Medications
https://clinicaltrials.gov/ct2/show/NCT00486954 Study ID: 104578 Clinical Study ID: EGF104578 Study Title: A Randomized, Multicenter, Open-label, Phase III Study of Lapatinib (GW572016) in Combination with weekly Paclitaxel versus weekly Paclitaxel alone in the second line treatment of ErbB2 amplified Advanced Gastric Cancer Patient Level Data: Clinicaltrials.gov Identifier: NCT00486954 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Product Sponsorship Transferred to Novartis Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Neoplasms, Gastrointestinal Tract CRF Seiten: 1288-1609

Eligibility Early Gastric Cancer NCT01643811

- 1/12/19 - 1 formulario, 2 itemgroups, 11 items, 1 idioma
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01643811

dbGaP phs000361 Genome-Wide Association Studies in Upper Gastrointestinal Cancers (Asian) - pht002221.v1.p1

- 12/10/22 - 4 formularios, 1 itemgroup, 3 items, 1 idioma
Itemgroup: pht002221
Principal Investigator: Philip R. Taylor, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA MeSH: Squamous Cell Carcinoma,Esophageal Cancer,Gastric Cancer https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000361 This project aims to conduct genome-wide association studies (GWAS) in two anatomically different upper gastrointestinal (UGI) cancer sites in two populations with distinctly different disease rates and genetic profiles. One population has very high rates for both esophageal squamous cell carcinomas (ESCCs) and gastric cancers (GCs) and is comprised of Asians (*the "Asian UGI GWAS"*), while the other population has low rates of ESCC and GC and includes non-Asians from the Americas, Europe, and Australia (*the "Non-Asian UGI GWAS"*). Study participants for the Asian UGI GWAS reported here (Illumina 660W Quad chip) were drawn from 2 studies, the Shanxi Upper Gastrointestinal Cancer Genetics Project (Shanxi) and the Linxian Nutrition Intervention Trial (NIT), a prospective cohort, and included a total of 1898 ESCCs, 1625 GCs, and 2100 controls. For the 2nd phase (8 TaqMan SNPs), additional subjects from Shanxi and NIT as well as subjects from the Shanghai Men's Health Study (SMHS), the Shanghai Women's Health Study (SWHS), and the Singapore Chinese Health Study (SCHS) were also included (217 ESCCs, 615 GCs, 1202 controls). Altogether 2115 ESCCs, 2240 GCs, and 3302 controls were genotyped in this study.

pht002222.v1.p1

1 itemgroup 2 items

pht002223.v1.p1

1 itemgroup 5 items

Eligibility

1 itemgroup 3 items

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Zytoreduktive Chirurgie / HIPEC Part 1

- 27/9/21 - 1 formulario, 6 itemgroups, 75 items, 1 idioma
Itemgroups: Administrative Documentation, Physical Examination, Laboratory Data, Cytoreductive Surgery, Peritoneal Cancer Index, Type of surgery
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Woche 12

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Zytoreduktive Chirurgie / HIPEC Part 2

- 2/9/21 - 1 formulario, 7 itemgroups, 65 items, 1 idioma
Itemgroups: Administrative Documentation, Postoperative questions, Result of Surgery, Pathological tumor staging, Tumor staging, HIPEC, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Woche 12

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Unerrwünschtes Ereignis

- 21/11/17 - 1 formulario, 3 itemgroups, 30 items, 1 idioma
Itemgroups: Administrative Documentation, Adverse Event, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Bitte faxen Sie die Seite umgehend an: Fax-Nr. 030 / 450 7 522 214

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Patientenrandomisation

- 21/11/17 - 1 formulario, 4 itemgroups, 42 items, 2 idiomas
Itemgroups: Administrative Documentation, Inclusion Criteria, Exclusion Criteria, Staging | stratification factors
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Studien-Patientenidentifikation Bitte tragen Sie den Patienten in die Patientenidentifikationsliste (PIL) in Ihrem Investigator Site File (ISF) ein , um dem Patienten eine Pat-ID zuzuweisen. Bitte faxen Sie die Seiten R_01 und R_02 umgehend an die Studienzentrale der Charité : 030 – 450 7 522 214

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Hospitalisierung

- 21/11/17 - 1 formulario, 2 itemgroups, 9 items, 1 idioma
Itemgroups: Administrative Documentation, Hospitalization
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Chirurgische Sekundärintervention

- 21/11/17 - 1 formulario, 2 itemgroups, 8 items, 1 idioma
Itemgroups: Administrative Documentation, Surgical intervention
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Bitte nur chirurgische Sekundärinterventionen dokumentieren, die unmittelbar durch Tumorprogress bedingt sind.

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Progress

- 20/11/17 - 1 formulario, 3 itemgroups, 16 items, 1 idioma
Itemgroups: Administrative Documentation, Progress, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Progress Hinweis: Bis Visit 10 (nach letztem Zyklus der Chemotherapie) bedeutet die Feststellung eines Progresses: Abbruch der Studientherapie: AS – Bogen ausfüllen Bei klinischem Tumorprogress (vor der OP - bis Woche 12) ist für diesen Patienten der Abbruch der Studientherapie zu beschließen. Patienten, die im Behandlungsarm B therapiert werden, soll die HIPEC ohne zytoreduktive Chirurgie (nach Ausschluss von Kontraindikationen) durchgeführt werden. Die Weiterbehandlung erfolgt nach Ermessen des behandelnden Arztes.

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Weitere Follow up

- 20/11/17 - 1 formulario, 12 itemgroups, 40 items, 2 idiomas
Itemgroups: Administrative Documentation, Physical Examination, Laboratory Data, Diagnostic procedures, Results, Concomitant therapy, Toxicities, Late toxicites, Progress, Adverse Event, Life quality, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Weitere Follow up (ab Monat 12 bis Studienende)

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial